Evidence Explorer · MS-N282 · Investigational drug repurposing · Appraised November 9, 2026
The large MA.32 randomized trial found that adding metformin to standard breast-cancer treatment did not improve invasive disease-free or overall survival in people without diabetes. Observational and laboratory signals did not translate into an overall adjuvant benefit.
Evidence at a glance
- Population: 3,649 people with high-risk, nonmetastatic breast cancer without diabetes.
- Intervention: metformin 850 mg twice daily versus placebo for five years alongside standard cancer treatment.
- Primary result: in hormone-receptor-positive disease, invasive disease-free-survival HR 1.01 (95% CI 0.84–1.21; P=.93); overall survival was also not improved. Hormone-receptor-negative results were similarly null.
- Evidence label: high-quality randomized negative evidence for routine adjuvant use in people without diabetes.
What was studied
MA.32 was international, double-blind and placebo-controlled. All 3,649 randomized participants were included in analysis, with median follow-up of about eight years in the hormone-receptor-positive group.
Exploratory HER2-positive and metabolic-marker subgroup findings remain hypothesis-generating. A 2026 analysis did not overturn the trial’s overall null result, and a 2026 neoadjuvant meta-analysis judged response evidence low to very low certainty.
What this evidence cannot establish
The trial does not question metformin’s established role in type 2 diabetes. It shows that prescribing it solely as routine adjuvant breast-cancer therapy to people without diabetes does not improve overall cancer outcomes.
Safety and practical context
Grade 3 nonhematologic toxicities were more frequent with metformin than placebo. Common clinical concerns include gastrointestinal effects and vitamin B12 reduction.
Rare lactic acidosis risk rises with renal impairment, hypoxia, hepatic impairment, heavy alcohol use, surgery and some contrast-imaging settings. Diabetes treatment should never be stopped because an oncology trial was negative.
Questions for the care team
- Is metformin needed for diabetes or being proposed only for cancer control?
- Does any claimed benefit come from a prespecified randomized subgroup or an exploratory analysis?
- How will kidney function, B12 and contrast-imaging plans be handled?
Sources and identifiers
- MA.32 randomized phase III trial — PMID 35608580
- 2026 exploratory metabolic-factor analysis — PMID 42063220
- 2026 neoadjuvant systematic review and meta-analysis — PMID 42399548
- Current US metformin prescribing information
Funding and conflicts: MA.32 was conducted by the Canadian Cancer Trials Group with public and nonprofit support. Detailed author conflicts are available in the primary report and were not fully re-extracted here.
Source access and dates: Original reports, registry records and official safety sources available through the links above were checked November 9, 2026. Last literature search November 9, 2026.
Educational evidence summary, not individualized medical advice. Investigational or repurposed products should not replace established cancer treatment. Symptom, biomarker, laboratory or animal findings do not establish tumor control, recurrence prevention or longer survival.
